Melean Visnick

USPTO Granted Patents = 48 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 4.3

ph-index = 20

Forward Citations = 1,010(Granted Patents)

Company Filing History:

46 out of 61

Reata Pharmaceuticals, Inc.

patents

2 out of 7

Reata Pharmaceuticals Holdings, LLC

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358866 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 (2025-07-15),

2. 12344631 - C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof (2025-07-01),

3. 12195443 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2025-01-14),

4. 12060340 - Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith (2024-08-13),

5. 11993574 - Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma (2024-05-28),

6. 11919838 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 (2024-03-05),

7. 11827664 - Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway (2023-11-28),

8. 11814338 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2023-11-14),

9. 11584775 - C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses (2023-02-21),

10. 11406648 - C17-heteroaryl derivatives of oleanolic acid and methods of use thereof (2022-08-09),

11. 11292781 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2022-04-05),

12. 11192852 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2021-12-07),

13. 11091430 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 (2021-08-17),

14. 11059792 - Imidazolyl tricyclic enones as antioxidant inflammation modulators (2021-07-13),

15. 10898499 - C17-heteroaryl derivatives of oleanolic acid and methods of use thereof (2021-01-26),

Title: Melean Visnick: Innovator in Pharmaceutical Patents

Introduction

Melean Visnick, based in Irving, TX, is a prominent inventor with an impressive portfolio of 46 patents. His contributions significantly advance the field of pharmaceuticals, particularly in the treatment of inflammatory and autoimmune disorders.

Latest Patents

Among Visnick's latest patented innovations are the pyrimidine tricyclic enone derivatives designed to inhibit ROR-gamma. These compounds and their pharmaceutical compositions may aid in reducing the expression of IL-17, thus contributing to the treatment and prevention of inflammatory diseases. Another notable patent involves cysteine-dependent inverse agonists of nuclear receptors ROR-gamma and ROR-gamma-t. This invention details methods for administering these inverse agonists to patients, enhancing the therapeutic approach in managing diseases linked to these nuclear receptors.

Career Highlights

Throughout his career, Melean Visnick has made significant strides in pharmaceutical research and development. He has worked with reputable organizations, including Reata Pharmaceuticals, Inc. and AbbVie Inc., where he has collaborated on innovative pharmaceutical solutions.

Collaborations

Visnick's work often involves collaboration with other esteemed professionals in the industry. Notable colleagues include Xin Jiang and Eric Anderson, contributing to a collective effort in advancing medical science through their innovative research.

Conclusion

Melean Visnick continues to be a trailblazer in the realm of pharmaceutical patents, with a focus on developing effective treatments for inflammatory and autoimmune disorders. His innovative spirit and dedication to research position him as a key figure in the advancement of therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.